Sort by
Refine Your Search
-
on drug development, uncovering basic mechanisms, and identifying novel therapeutic targets in leukemogenesis and solid tumors. Specifically, we study genetic and epigenetic biomarkers with prognostic value
-
are looking for a highly motivated candidate with a PhD and/or MD degree interested in combining novel rational and combinatorial synthetic biology approaches with computational methods to develop strategies
-
Epigenetics, Epigenetics Regulation, Cancer Metabolism, Immunology, Drug Discovery, Development, and Structural Biology, with an emphasis on RNA epigenetics/epitranscriptomics (RNA modifications) and RNA-based
-
of Hope. This role offers an exciting opportunity to investigate immune checkpoint signaling within the tumor microenvironment and contribute to the development of novel anticancer therapies
-
: · Develop and maintain clinical and translational research trials in genitourinary cancers. · Collect, analyze, and maintain large databases pertaining to genitourinary cancers. · Draft
-
pharmacology tools to identify novel signaling pathways in metabolism to develop new targets for drug discovery. Our research interests include: 1) Liver-gut and microbiota crosstalk as metabolic mediators in
-
to vaccine development utilizing viral vectors to contribute to an effort in developing neoantigen expressing vaccines for clinical investigations. The position is available as part of a multi-disciplinary
-
Biology, Chromatin Regulation, Cancer Epigenetics, Epigenetics Regulation, Cancer Metabolism, Immunology, Drug Discovery, Development, and Structural Biology, with an emphasis on RNA epigenetics
-
drive our multiomics, high-throughput sequencing projects and help develop any projects based on the most advanced technologies. Your qualifications should include: Ph.D. in Biochemistry, Bioinformatics
-
) development of small molecule drugs and PROTAC-drug conjugates. The Li group conducts the most forefront science and is highly productive with publications in high-impact journals in the past five years, Nature